ArticleCost effectiveness and resource allocation : C/E2018

Cost-effectiveness of ustekinumab in moderate to severe Crohn's disease in Sweden.

Amanda Hansson-Hedblom et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.